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ABSTRACT
INTRODUCTION: Hypophosphataemic rickets (HR) is a rare 
hereditary disease characterised by hypophosphataemia, 
defects in bone mineralisation and rickets.
MATERIAL AND METHODS: We searched the hospital files at 
H.C. Andersen Children’s Hospital, Odense University Hos­
pital, Denmark, for children with the International Classifi­
cation of Diseases 10 codes E83.3B (vitamin D resistant rick­
ets) and E83.3A1 (familiar hypophosphataemia) from 1 
February 2012 to 1 May 2012. Data were collected retro­
spectively. 
RESULTS: Fifteen HR children were identified. X­linked 
hypo phosphataemia with mutations in the phosphate­regu­
lating endopeptidase homologue, X­linked were present in 
80%; three had autosomal recessive HR with dentin matrix 
protein mutations. The children were treated with phos­
phate and alphacalcidol for an average of 7.7 years ± 5.1 
standard deviations (SD). At the latest follow­up, the mean 
age was 10.1 (+5.4) years, and the mean height had de­
clined 0.8 SD from the first contact. A total of 40% had an 
actual height below –2.0 SD, and 40% underwent surgery 
for leg deformities. Among the medically treated patients, 
five had genu varus with a mean medial femoral condyle 
distance of 6.6 cm (+ 2.79), and two patients had genu val­
gus with a mean medial malleolus distance of 12.3 cm (+ 
1.77). Episodes of secondary hyperparathyroidism were 
seen in 87%, and one patient developed transient nephro­
calcinosis. 
CONCLUSION: The current medical treatment for HR is in­
sufficient. The rarity of the disease and the treatment diffi­
culties of HR call for centralised management. International 
multi­centre trials including novel treatment options are 
warranted. 
FUNDING: not relevant.
TRIAL REGISTRATION: not relevant.
Hypophosphataemic rickets (HR) is a type of hereditary 
rickets characterised by hypophosphataemia secondary 
to urinary phosphate loss and defective bone mineralisa­
tion. X­linked dominant hypophosphataemic rickets 
(XLH) is the most common form with an estimated inci­
dence of 3.9 per 100,000 live births [1]. XLH is caused by 
a dominant inactivating mutation in the gene phos-
phate-regulating endopeptidase homologue X-linked 
(PHEX). Autosomal recessive hypophosphataemic rickets 
(ARHR1) is a more seldom variant which is caused by 
mutation in the dentin matrix protein (DMP1).  Auto­
somal dominant hypophosphataemic rickets (ADHR) is 
another rare type of HR caused by mutation in fibroblast 
growth factor 23 (FGF23). These gene mutations all re­
sult in increased FGF23, which regulates the phosphate 
homeostasis [2]. 
There is a tendency for men with XLH to have more 
severe skeletal affection than women. This may be due 
to the fact that men only carry activated, mutated X 
chromosomes, whereas women, carrying two X chromo­
somes per cell, inactivate a proportion of the mutated X 
chromosomes [3].
Medical treatment is difficult and consists of oral 
phosphate and alphacalcidol (1­alpha­hydroxy vitamin 
D). The optimum dose of phosphate is uncertain, but 
some clinicians recommend 20­40 mg/kg/day, with  
higher doses during high­growth periods. Phosphate 
needs to be administered 3­5 times daily, which often 
leads to gastrointestinal side effects [4]. A dosage of 
0.03­0.05 microgram/kg of alphacalcidol is recom­
mended once daily [5]. Some clinicians advocate for a 
higher alphacalcidol dose in the initial phase, but this 
has not been evaluated compared to lower doses. 
Even timely treatment with a high level of adher­
ence cannot completely normalise bone growth, and 
various degrees of bone deformity and reduced height 
are unavoidable [3, 6]. Furthermore, side effects to the 
treatment are likely to arise, such as secondary hyper­
parathyroidism (SHPT) and nephrocalcinosis [7].
We made a retrospective follow­up of children with 
HR followed at the Hans Christian Andersen Children’s 
Hospital, Odense University Hospital (OUH), Denmark, to 
evaluate the efficacy and any complications of the cur­
rent treatment regimen.
MATERIAL AND METHODS
We identified HR patients at OUH by searching the hos­
pital files for children with the the International Classi­
fication of Diseases (ICD) 10 codes E83.3B (D­vitamin 
 resistant rickets) and E83.3A1 (familiar hypophosphat­
aemia) during the period from 1 February to 1 May 
2012. Permission was granted from the Danish Data Pro­
tection for collecting sensitive personal data. Existing re­
cords were reviewed for gender, age and height at diag­
Treatment of hypophosphataemic rickets in children 
remains a challenge
Line Hougaard Nielsen1, Elise Torp Rahbek1, Signe Sparre Beck­Nielsen2, 3 & Henrik Thybo Christesen3, 4
ORIGINAL 
ARTICLE
1) Faculty of Health, 
University of South 
Denmark, Odense
2) Department of 
Paediatrics, Hospital of 
Southwest Denmark, 
Esbjerg
3) Institute of Clinical 
Research, University of 
South Denmark, 
Odense
4) Hans Christian 
Andersen Children’s 
Hospital, Odense 
University Hospital
  
Dan Med J
2014;61(7):A4874
 2  DA N I S H M E D I C A L J O U R N A L Dan Med J 61/7  July 2014
nosis and at follow­up. Furthermore, we registered gene 
mutations, known HR in the family, number of visits per 
year, the most recent medial femoral condyle distance 
and medial malleolus distance, medical treatment, bone 
deformity correcting surgeries and nephrocalcinosis de­
tected by ultrasound of the kidney/urinary tract. Fur­
thermore, the average phosphate and alphacalcidol dos­
ages were registered from the initiation of medical 
treatment to the end of the study period or until bone 
deformity­corrective surgery. Based on these data, we 
calculated an average dose for each patient and the 
overall median/(range) dosage.
The average number of reported phosphate admin­
istrations per day during the years of medical treatment 
was used as an estimate of treatment adherence. Phos­
phate administrations 4­5 times/day was defined as 
good adherence, 3 times/day was medium adherence 
and 1­2 times/day was poor adherence.   
SHPT was defined as the detection of at least one 
measurement of serum parathyroid hormone (S­PTH) 
above the upper reference value (> 6.90 pmol/l).
Height standard deviations (SD) score was calcu­
lated from the reference curve used at the department 
[8] using the software NordiNet 3.2. For statistical calcu­
lation, the Shapiro­Wilk test, t­distribution and Welch’s 
unpaired t­test were used. A p­value < 0.05 was con­
sidered statistically significant.
Trial registration: not relevant.
RESULTS
Fifteen patients with HR were identified. The patients 
came from Funen (n = 11), other parts of the Region of 
South Denmark (n = 1) and other areas of Denmark  
(n = 3).
XLH represented 80% (n = 12). The remaining 20% 
(n = 3) had ARHR1 (Table 1). The sex ratio (girl:boy) was 
3:2. Eleven patients had relatives with known HR at the 
time of their diagnosis. The average age ± standard devi­
ation (± SD) at diagnosis was 2.0 ± 1.6 years, whereas 
the mean baseline height SD was –0.9 ± 1.2 (Table 2). In 
20% of the patients (n = 3), the height was below –2.0 
SD. At the time of diagnosis, the patients who were diag­
nosed before the age of seven months had a higher 
height SD than patients diagnosed after the age of seven 
months. The median number of visits per year was three 
(Table 3). 
The average duration of treatment was 7.7 ± 5.1 
years, Table 1. At the end of the study period, one pa­
tient was not receiving any medical treatment due to 
SHPT and poor compliance. All other patients were be­
ing treated with phosphate and alphacalcidol. The over­
all median phosphate dosage was 32.8 mg/kg/d (range 
4.6 to 82.0); alphacalcidol 0.04 microgram/kg/d (range 
0.0 to 0.15). A good adherence to treatment was ob­
served in 67%, whereas 27% had medium adherence 
and 6% had poor adherence to treatment, Table 3. The 
adherence to treatment was not correlated with height 
SD (p = 0.10).
TABLE 1
Basic characteristics of hypophosphataemic rickets patients.
Age, yrs; months
Patient no. Gender
time of  
diagnosis
latest  
follow-up
Treatment  
duration, yrs
Affected 
gene
Family  
member with 
known HR
1 Girl 0; 6 2; 7   2.08 DMP1 Yes
2 Girl 1; 2 16; 10 15.54 PHEX Yes
3 Girl 3; 3 11; 5   8.17 PHEX No
4 Girl 0; 7 6; 5   5.83 PHEX Yes
5 Girl 0; 5 2; 7   2.17 PHEX Yes
6 Girl 2; 6 11  11   9.42 PHEX No
7 Girl 6; 1 13; 7   2.31 PHEXa Yes
8 Girl 1; 8 7  5   5.75 PHEXa Yes
9 Girl 2; 6 14; 5 11.92 PHEX N/A
10 Boy 3; 8 10; 11   7.25 DMP1 Yes
11 Boy 1; 8 5; 1   3.42 DMP1 Yes
12 Boy 2; 6 19; 2 16.5 PHEX Yes
13 Boy 0; 2 11; 5 11.12 PHEX Yes
14 Boy 2; 3 15; 5 13.17 PHEX No
15 Boy 1; 3 2; 9   1.5 PHEXa Yes
Average – 2; 0 10; 2   7.7 – –
DMP1 = dentin matrix protein; HR = hypophosphataemic rickets; N/A = data not available; PHEX = 
phosphate-regulating endopeptidase homologue X-linked. 
a) Mutation associated with the PHEX gene detected by linkage analysis [3].
TABLE 2
Height data and parathyroid hormone values.
Patient 
no. baseline latest follow-up Δ height SD
PTHmax for  
patients with  
SHPT, pmol/l
1   0.02 –1.50 –1.52   8
2 –2.05 –0.92 1.13 –a
3 –0.45 –2.12 –1.67   9.9
4   0.99 –2.63 –3.62 12.5
5   0.92 –0.99 –1.91 16.4
6 –2.86 –1.36 1.50   9.5
7 –0.20   0.11 0.31 13.4
8 –0.79 –0.93 –0.14 –a
9 –2.30 –2.72 –0.42 10.1
10 –1.23 –1.32 –0.09   9.7
11 –1.51 –1.21 0.30 10.6
12 –3.10 –2.80 0.30 16.5
13 –0.30 –2.70 –2.4 11.5
14 –1.05 –2.87 –1.82 15.7
15 –0.24 –1.79 –1.55   7.5
Average –0.9 –1.7 –0.8 11.6
PTH = parathyroid hormone; SD = standard deviation; SHPT = secondary 
hyperparathyroidism. 
a) No elevated PTH values. 
Height SD
Dan Med J 61/7  July 2014 DA N I S H M E D I C A L J O U R N A L   3
At the latest follow­up, the average age was 10.1 ± 
5.4 years and the mean height SD –1.7 ± 0.9, Table 2). 
Mean Δ height SD from baseline was –0.8 ± 1.4. At the 
last follow­up, 40% (n = 6) had a height below –2.0 SD. 
Initiation of treatment before the age of two years was 
not correlated with increased height SD at the latest fol­
low­up (p = 0.57).
Among the XLH patients, there were no differences 
in Δ height SD between genders, (girl:boy) ratio (2:1).
A total of 40% (n = 6) went through one or more 
bone deformity corrective surgeries of the lower limbs, 
with an average of two surgeries per patient. At the 
most recent follow­up, three patients were below the 
age recommended for surgical intervention.
Of the patients with no surgeries, five had genu  
varus (Figure 1) with an average medial femoral condyle 
distance of 6.6 ± 2.8 cm, and two patients had genu val­
gus with an average medial malleolus distance of 12.3 ± 
1.8 cm. Two patients (girls) aged 14 and 16 years had no 
deformities of the lower limbs. Only one patient had 
transient nephrocalcinosis following an accidental over­
dosing of phosphate. Among the patients, 87% (n = 13) 
had at least one case of SHPT with an average PTHmax of 
11.6 pmol/l, (Table 2). 
DISCUSSION
Despite an average of 7.7 years of medical treatment at 
a specialist centre with median dosages within the inter­
nationally recommended range, many patients re­
mained severely affected at the most recent follow­up 
with either genu valgus or varus, and 40% had an actual 
height below –2.0 SD. Furthermore, 40% had undergone 
surgery for leg deformities. A decline in the height SD 
with age was present among medically untreated as well 
as among medically treated patients. Thus, in our study, 
HR was associated with a progressive decrease in height 
SD, which was not compensated for by the current 
methods of treatment. 
Other studies [3, 7, 9] also find that HR often results 
in growth retardation with a reduced final height and leg 
deformities requiring surgery despite medical treat­
ment. 
The disease exerts its effect on bone mineralisation 
already before HR becomes clinically symptomatic. The 
leg deformities are usually already present at the time of 
diagnosis. Studies [10, 11] find a trend towards in­
creased height when treatment is initiated within the 
first year of life. In families with known cases of HR,  
diagnosis and treatment shortly after birth may de­
crease the severity of bone deformations. In our study, 
73% of the included patients had relatives with HR. Eight 
patients initiated medical treatment before the age of 
two years. Nevertheless, no difference in height SD at 
the latest follow­up could be detected between this 
group and the group with later on­set of treatment. This 
may be due to low statistical power. 
We argue that the number of phosphate adminis­
trations per day is the best estimate of adherence, given 
that only a few clinicians followed the patients in the 
outpatient clinic and hence adjusted the number to ad­
herence.  However, no difference in Δ height SD could 
be detected between daily phosphate dose groups.
The incidence of nephrocalcinosis visualised by  
ultrasound in the present study was low compared with 
other studies [7]. The presence of nephrocalcinosis in 
one patient in our study was entirely caused by an unin­
tended, increased phosphate dosage. We found no dif­
ference by gender in Δ height SD among XLH patients, 
whereas previous studies including adults with HR show 
a tendency towards a more severe skeletal affection in 
men [6]. This may be due to young age among our pa­
tients, a possible lack of diagnosis and referral of mildly 
affected girls, or low statistical power. 
SHPT was a very frequent complication, which 
would lead to a necessary reduction of the phosphate 
dosage. Low phosphate dosage and SHPT in itself may 
both lead to decreased bone mineralisation. Thus, pre­
venting SHPT has high priority. In our series, experimen­
tal treatment with Cinacalcet was not performed. 
Cinacalcet has been used in some patients with HR [12­
14], but a recent case describing hypocalcaemia with fa­
tal outcome during Cinacalcet treatment in children has 
lead to a current suspension of all paediatric clinical tri­
als with Cinacalcet.
As increased FGF23 is part of the pathogenesis of 
TABLE 3
Dosage, adherence and visit frequency.
Patient  
no.
Mean phos- 
phate dosage,  
mg/kg/d
Mean alpha- 
calcidol dosage, 
 µg/kg/d Adherence Visits/yr, n
1 26.5 0.03 Good 4
2 31.2 0.04 Medium 3
3 82.0 0.02 Good 2
4 54.2 0.15 Good 3
5 14.2 0.01 Good 1
6 74.3 0.06 Good 4
7   4.6 0.00 Poor 2
8 16.9 0.004 Medium 1
9 67.4 0.05 Good 2
10 32.8 0.04 Good 4
11 39.7 0.03 Good 4
12 30.3 0.06 Medium 3
13 57.8 0.06 Good 3
14 47.6 0.10 Good 3
15   8.5 0.01 Medium 2
Median 
(range)
32.8 (4.6­82.0) 0.04 (0.0­0.15) – 3 (1­4)
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HR, some experimental trials for future treatment focus 
on decreasing the FGF23 level. In mouse models of XLH 
(HYP­mice), treatment with FGF23 antibodies has re­
sulted in partial healing of rickets [15]. In addition, treat­
ment of HYP­mice with FGF23 antagonist has shown im­
provement of bone mineralisation and growth [16]. One 
available study showed promising results after one sin­
gle treatment with FGF23 antibodies/antagonists in HR 
adults [17].
A strength of our study was the inclusion of a rela­
tively large number of patients, the rarity of the disease 
taken into account, and the use of a uniform treatment 
strategy. Limitations included the retrospective design 
and the risk of intra­ and inter­observer variability in the 
clinical assessment of genu valgus/varus and medial 
malleolus distance. In addition, we did not correct for 
the physiological genu varus and valgus, which is primar­
ily present below the age of five years [18].
CONCLUSION
In summary, we showed that despite a modern treat­
ment regimen, HR causes reduced height and consider­
able lower limb deformities. The rarity of the disease 
and its complexity justify centralised management. New 
treatment options should be tested in international 
multi centre controlled studies.
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